Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …
BEVERLY, MA–(Marketwire – 07/07/10) – Cellceutix Corporation (OTC.BB: CTIX – News ) today announced that it has completed all three animal safety pharmacology studies for its cancer compound, Kevetrin, that are required by the U. S. Food and Drug Administration prior to filing an IND. These studies involve assessments of the impact of the administration of a compound on the respiratory …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: animal, cancer, Cellceutix, Completes, compound, Pharmacology, prior, required, Safety, Studies, three
Cardiff U Launches Three New Research Institutes
Cardiff U Launches Three New Research Institutes
NEW YORK (GenomeWeb News) – Cardiff University in Wales will invest £10 million ($14.8 million) into three new multidisciplinary research institutes. The first among these is the Cancer Stem Cell Research Institute, which aims to conduct studies that will lead to new cancer therapies.
Read more on GenomeWeb News
Categories: Breast Cancer Organizations Tags: Cardiff, Institutes, Launches, research, three
Parp Drugs – A New Cancer Inhibitor Soon To Pass Phase Three
A PARP is also known as a Poly (ADP-ribose) polymerase and it repairs damage done to our body, it is a useful function and basically a PARP enzyme regulates our body, repairing damaged DNA. Usually this is a normal function which stops cell death however Doctor de Bono and his colleagues have done research to suggest that cancer cells may use PARP repair method to their advantage.
An inhibitor cancer drug is a new type of cancer treatment which inhibits (stops) a function that cancer uses to its advantage. One of these is the PARP function. Currently PARP inhibitor clinical trials are featuring two parp drugs named BSI 201 (BiPar Sciences) and Olaparib (Astra Zeneca). These PARP inhibitors are in phase two trials and have been proclaimed to be a major breakthrough in cancer research.
PARP Inhibitors are currently being trialled for use in ovarian, breast and prostate cancer and are being trialled targeting mutations in the BRCA1 and BRCA2 genes. One of the reasons this drug is such a promising target is that it has shown significant anti-tumor effects and yet has caused no side effects (doesn’t appear needed for general healthy functioning) for those that have received the parp inhibitors. If PARP trials prove to be successful this may be one of the most exciting cancer treatments we have seen for a long time.
Currently one woman on the trial has shown a full recovery from advanced PARP breast cancer, whilst this is not a cure for cancer it has shown promising early signs in one third of those treated has reduced the size of tumors.
For more information please go to parp-inhibitors.com.
What are the survival percentage rates for a woman with stage three c breast cancer?
She has had a mastectomy, chemotherapy, and radiation. She is currently taking the drug Femara. She is two years into the disease and has had no tumors but still has high tumor markers and uptake in the spine showing on pet-scans.So What do you think her survival rate is?
Categories: Breast Cancer Staging Tags: breast, cancer, percentage, Rates, Stage, Survival, three, Woman
Three Pulmonary Fibrosis Organizations Unite For National ‘Blue Shirt Friday’ Campaign
Three Pulmonary Fibrosis Organizations Unite For National ‘Blue Shirt Friday’ Campaign
SAN JOSE, Calif., April 9 /PRNewswire-USNewswire/ — The Coalition for Pulmonary Fibrosis, The Pulmonary Fibrosis Foundation and the Pulmonary Fibrosis Association of Texas today announced the launch of a special, grassroots campaign to build increased national awareness of Pulmonary Fibrosis (PF).
Read more on redOrbit